B-type natriuretic peptide in hypertensive crises: Diagnostic use in hypertensive urgencies and emergencies  by El Maraghi, Sameh et al.
The Egyptian Journal of Critical Care Medicine (2013) 1, 61–67The Egyptian College of Critical Care Physicians
The Egyptian Journal of Critical Care Medicine
http://ees.elsevier.com/ejccm
www.sciencedirect.comORIGINAL ARTICLEB-type natriuretic peptide in hypertensive crises:
Diagnostic use in hypertensive urgencies and emergenciesSameh El Maraghi b,*, Hend Yahia a, Ayman Heikal a, Mohamed Ashraf aa Critical Care Department, Faculty of Medicine, Cairo University, Egypt
b Critical Care Department, Faculty of Medicine, Beni Suef University, EgyptReceived 1 December 2012; revised 26 December 2012; accepted 3 January 2013












90-7303  2013 The Egyptia
en access under CC BY-NC-ND li





y of TheAbstract Background: It is not so easy to make a quick screening between hypertensive emer-
gency (HE) and hypertensive urgency (HU), as it often requires sophisticated, complex and time
consuming clinical, instrumental and diagnostic tests.
Aim: To address the role of B-type natriuretic peptide (BNP) in hypertension and how to use it
to differentiate HE from HU to alleviate possible complications.
Methods: A total of 30 patients with rapid severe elevation of blood pressure (BP) admitted to
the in-patient wards and critical care department, Cairo University, were included in a prospective,
non-interventional study. On the basis of the clinical ﬁndings, patients were subdivided into two
groups: Group I: 15 patients with HE with acute organ involvement and group II: 15 patients with
HU without acute organ damage. Another 10 patients with chronic hypertension were taken as con-
trol group. BNP was measured in the blood at the time of admission based on the principle of com-
petitive enzyme immunoassay.
Results: There was no signiﬁcant correlation between the patients’ age (58.5 ± 12) and BNP level
(183.67 ± 216.3) (r= 0.17, p= 0.3) and also there was no signiﬁcant difference in BNP blood level
between males (223.35 ± 179.2) and females (131.77 ± 255.2) (p= 0.26) and it was signiﬁcantly
higher in HE patients (324.33 ± 233.16) than HU patients (43 ± 13.5) and control group
(8.13 ± 5.8) with p-value of <0.001. There was no signiﬁcant difference in BNP level between HE
patients with cardiac (313.33 ± 179.6) and neurological involvement (313.67 ± 273.5) (p= 0.8),
also, there was no signiﬁcant difference in BNP level between patients presented with ischemic stroke
(248.75 ± 171), hemorrhagic stroke (255 ± 132) and hypertensive encephalopathy (970) (p= 0.3).
Moreover, there was no signiﬁcant correlation between BNP and systolic BP, diastolic BP, mean arte-
rial pressure and pulse pressure in both studied patients and control groups (p> 0.05 in all). Receivero.com (S. El Maraghi).
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62 S. El Maraghi et al.operator characteristic (ROC) curve was calculated for the use of BNP level as a diagnostic marker.
The area under curve (AUC) for BNP as a diagnostic marker was 0.96.
Conclusion: During hypertensive crises BNP blood level determination could have a role as a diag-
nostic tool for the screening ofHE and its evaluation is very useful in patients admitted with acute and
rapid elevation of BP to limit target organ damage.
 2013 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V.
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Hypertensive crisis is characterized by a rapid, often symptom-
atic rise in blood pressure (usually with diastolic blood pres-
sure [DBP] > 120 mmHg) in patients both with known or
unknown arterial hypertension [1].
The pathophysiology of this clinical condition is mainly due
to a sudden elevation of systemic vascular resistance [2], and
the magnitude of the BP elevation is probably less important
than the rapidity of the increase [3].
Hypertensive emergencies [HE] encompass a spectrum of
clinical presentations where elevation of BP is complicated
by evidence of impending or progressive target organ dysfunc-
tion [4]. The most important complications include ischemic
stroke, hypertensive encephalopathy, hemorrhagic stroke and
myocardial ischemia [5]. Morbidity and mortality depend on
the extent of organ damage at presentation and on the degree
of BP reduction [6].
On the other hand, Hypertensive urgency [HU] is a severe
elevation in BP without progressive target organ dysfunction
[4].
B-type natriuretic peptide (BNP), with the inactive frag-
ment N-terminal pro hormone brain natriuretic peptide (NT-
proBNP), is a peptide synthesized by atrial and ventricular
cardiomyocytes, with a potent vasodilator, diuretic and natri-
uretic action; it decreases sympathetic outﬂow and inhibits
vasopressin release [7].
The contribution of the measurement of BNP and NT-pro
BNP to the diagnosis and the prognosis of both acute heart
failure and coronary syndromes has been well documented
[8,9].
Aim of the work
There are no enough data on the potential diagnostic and
prognostic role of BNP detection in distinguishing between
HE and HU. In the following study we will try to address
the role of BNP in hypertensive crises and how to use it to dif-
ferentiate HE from HU to alleviate possible complications.
Patients and methods
Patients
The study protocol was approved by the local ethical commit-
tee. We prospectively enrolled thirty patients with rapid severe
elevation of BP, admitted to the in-patient wards and critical
care department, Cairo university hospitals; from August
2010 to February 2011. Informed consent was given by the pa-
tient or immediate relative (ﬁrst degree). This study did not
interfere with the medical decision toward the patient. Noinvasive medical procedure is required by the protocol. Every
patient received the optimum treatment that suits his medical
condition.
Exclusion criteria
Patients with age <18 and >90 years, heart failure, atrial
ﬁbrillation, primary pulmonary hypertension, chronic kidney
impairment (serum creatinine level >2.5 mg/dl), liver cirrho-
sis, thyrotoxicosis, neoplasms, chest trauma or pregnancy, as
these conditions may be associated with increase in BNP level.
Inclusion criteria
Patients who did not meet any of the exclusion criteria were se-
lected prospectively and included into the study.
On the basis of the clinical ﬁndings, patients were subdi-
vided into two groups: Group I: 15 patients with HE due to
the following acute organ involvement (heart; acute coronary
syndrome or brain; hypertensive encephalopathy, acute cere-
bral ischemia, hemorrhagic stroke); diagnosis of stroke and
myocardial ischemia was performed according to diagnostic
criteria of international guidelines [10–12]; and group II: 15
patients with HU without acute organ damage. Another 10
patients with chronic hypertension were taken as control
group.
All included patients were subjected to the following
Full clinical evaluation
Including present history of the disease and past history of
chronic hypertension and physical examination with special
emphasis on blood pressure determination; systolic and dia-
stolic BP were measured by a non invasive technique from left
and right arms. The average of two consecutive readings taken
30 s apart was used.
Laboratory investigations
Routine labs. CBC (complete blood count): Hemoglobin,
Hematocrit, White blood cells and platelet count, Coagulation
proﬁle: PT (prothrombin time), PC (prothrombin concentra-
tion), INR and PTT (partial thromboplastin time), Liver func-
tion tests: ALT (Alanine aminotransferase), AST (Aspartate
aminotransferase), BIL (bilirubin) total and direct and
albumin, Kidney Function Tests: Na, K, Creatinine and Urea,
Thyroid proﬁle (freeT3 freeT4, and TSH), Cardiac enzymes
(CPK, LDH, CM-MB) and troponin.
These routine Labs were withdrawn on day 1 of the study.
Speciﬁc labs. BNP measurement: This was done by the use of
BNP-32 (human) EIA kit provided by Phoenix pharmaceuti-
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related peptides based on the principle of competitive enzyme
immunoassay.
Blood sampling. Blood samples were collected from patients on
admission as follows: 7 ml of venous blood were drawn into
tubes containing EDTA for anticoagulation and aprotinin
(protease inhibitor), each tube was gently rocked for several
times immediately after collection of blood to prevent blood
clotting and inhibit the activity of proteases, then centrifuged
at 1600g for 15 min at 4 C and plasma was collected in eppen-
dorf tubes and kept at 70 C till analysis.
Principle of the assay. The immunoplate in the kit is precoated
with secondary antibody and the non speciﬁc binding sites are
blocked. The secondary antibody can bind to the Fc fragment
of the primary antibody (peptide antibody) whose Fab frag-
ment will be competitively bound by both biotinylated peptide
and peptide standard or targeted peptide in samples. The bio-
tinylated peptide interacts with streptavadine–horseradish per-
oxidase (SA–HRP) which catalyzes the substrate solution. The
intensity of the yellow is directly proportional to the amount of
biotinylated peptide-SA-HRP complex but inversely propor-
tional to the amount of the peptide in standard solutions or
samples. This is due to the competitive binding of the biotinyl-
ated peptide with the standard peptide or samples to the pep-
tide antibody (primary antibody). A standard curve of known
concentration was established accordingly. The unknown con-
centration in samples can be determined by extrapolation to
this standard curve.
Calculation of results. The standard curve was plotted on semi-
log graph paper. It was constructed by plotting the known con-
centrations of standard peptide on the log scale and its corre-
sponding OD reading on the linear scale. The standard curve
shows an inverse relationship between peptide concentrations
and the corresponding absorbance. As the standard concentra-
tion increases, the yellow color decreases, thereby reducing the
OD absorbance.
Standard 12 leads ECG
To detect ischemia and to exclude atrial ﬁbrillation.
Imaging studies
(a) Echocardiography; was done for all patients to assess the
left ventricular function and to exclude pulmonary
hypertension.
(b) CT brain was also performed to patients with cerebro-
vascular events when suggested by clinical condition.Statistics
Data were statistically described in terms of range; mean and
standard deviation (SD), median, frequencies (number of
cases) and relative frequencies (percentages) when appropriate.
Comparison of quantitative variables between the study
groups was done using unpaired student’s t-test for indepen-
dent samples when comparing 2 groups and Kruskal Wallis
test with posthoc multiple 2-group comparisons when compar-
ing more than 2 groups. For comparing categorical data, Chisquare (v2) test was performed. Exact test was used instead
when the expected frequency is less than 5. Accuracy was
represented using the terms sensitivity and speciﬁcity. Receiver
operator characteristic (ROC) analysis was used to determine
the optimum cut off value for the studied diagnostic markers.
Correlation between various variables was done using Spear-
man rank correlation equation for non normal variables. A
probability value (p-value) less than 0.05 was considered statis-
tically signiﬁcant. All statistical calculations were done using
computer programs Microsoft Excel 2003 (Microsoft Corpora-
tion, NY, USA) and SPSS (Statistical Package for the Social
Science; SPSS Inc., Chicago, IL, USA) version 15 for Micro-
soft Windows.Results
Demographic and baseline clinical data at ICU admission
Tables 1 and 2.
BNP and baseline clinical characteristics
There was no statistically signiﬁcant correlation between the
age of the patients (58.5 ± 12) and BNP level
(183.67 ± 216.3) (r= 0.17, p= 0.3). Also there was no sig-
niﬁcant difference in BNP level between males
(223.35 ± 179.2) and females (131.77 ± 255.2) (p= 0.26).
BNP blood level between both HE and HU groups and control
group
BNP was signiﬁcantly higher in HE patients (324.33 ± 233.16)
than HU patients (43 ± 13.5) and control (8.13 ± 5.8) groups
with p-value of <0.001 (Table 3 and Fig. 1).
BNP levels in hypertensive emergency group
There was no signiﬁcant difference in BNP level between HE
patients with cardiac (313.33 ± 179.6) and neurological
involvement (313.67 ± 273.5) (p= 0.8). There was no signiﬁ-
cant difference in BNP level between patients presented with
ischemic stroke (248.75 ± 171), hemorrhagic stroke
(255 ± 132) and hypertensive encephalopathy (970) (p= 0.3).
BNP levels in relation to blood pressure
1. There was no signiﬁcant correlation between BNP and SBP
in both studied patients and control groups (p> 0.05)
(Table 4).
2. There was no signiﬁcant correlation between BNP and
DBP in both studied patients and control groups
(p> 0.05) (Table 5).
3. There was no signiﬁcant correlation between BNP and
MAP in both studied patients and control groups
(p> 0.05) (Table 6).
4. There was no signiﬁcant correlation between BNP and PP
in studied patients and control groups (p> 0.05)
(Table 7).











SBP (mmHg) 207 ± 18.7 211.3 ± 18.8 203 ± 18.3 140 ± 10.12
DBP (mmHg) 127.8 ± 7.9 129.7 ± 7.3 126 ± 6 84.5 ± 4.97
MAP (mmHg) 154 ± 9.9 156.6 ± 11 151.6 ± 8 104.89 ± 5.0
Pulse pressure (mmHg) 79 ± 16.3 81 ± 15 77 ± 17.7 56 ± 10.74
Serum creatinine (mg/dl) 1.05 ± 0.24 1.06 ± 0.23 1.04 ± 0.26 0.88 ± 34
DM (%) 46.6% 40% 53.3% 40%
Patients with no past history of HTN (%) 13.3% 6.7% 20% –
Results are expressed as mean ± SD. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; DM, diabetes
mellitus.
Table 1 Demographic and clinical data of patients and controls in the study.
Characteristics Patient’s gp. Control gp.
Age, mean ± SD in years (range) 58.5 ± 12 (29–74) 59.7 ± 8.96 (49–78)
Male:female sex (ratio) 17:13 6:4
Classiﬁcation of the patients (N of patients (%))
Hypertensive urgency 15 (50%) –
Hypertensive emergency 15 (50%) –
Statistical distribution of target organ dysfunction
Acute coronary syndrome 6 (40%) –
Ischemic stroke 4 (26.7%) –
Heamorrhagic stroke 4 (26.7%) –
Hypertensive encephalopathy 1 (6.6%) –
Figure 1 BNP level in HE, HU and control groups.
Table 3 Comparison of BNP level between HE, HU and
Control groups.
Patients No. Mean SD p-Value
BNP HE 15 324.33 233.16 <0.001
HU 15 43 13.5
Control 10 8.13 5.8
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Receiver operator characteristic (ROC) curve was calculated
for the use of BNP level as a diagnostic marker. The area
under curve (AUC) for BNP as a diagnostic marker was 0.96
(Fig. 2).Discussion
The natriuretic peptides have a vital counter regulatory role in
clinical settings. Elevations of blood pressure and increased
ventricular and vascular wall stress typically trigger an up
regulation of BNP gene expression [13]. Several studies showed
that BNP appears to be released in response to increased wall
stress. Ischemia can cause transient LV systolic and diastolic
dysfunction [14,15].
There was no enough data on the potential diagnostic and
prognostic role of BNP detection in distinguishing between HE
and HU. Therefore, we tried in this study to assess the role of
BNP in the course of hypertensive crisis, to evaluate the possi-
ble role of BNP in the differential diagnosis between HE and
HU; and to investigate the relationship between BNP concen-
tration and BP acute burden with consequent myocardial
ischemia or brain damage.
Our study was conducted on 30 patients whose age ranged
from 29 to 74 years (mean age 58.5 ± 12). We compared BNP
in different ages and found that there is no signiﬁcant correla-
tion between BNP and age (p= 0.3 and r= 0.17).
This is in agreement with Ian Loke et al. [16], who found
that plasma BNP is not inﬂuenced by age, in contrast to N-ter-
minal pro-Atrial and N-terminal pro-B-type natriuretic pep-
tides which showed positive correlation with 16% and 74%
increase respectively in their levels for each 10 years of age.
Other studies done by Redﬁeld et al. [17], Wang et al. [18],
and Di Somma et al. [19], found that BNP increased signiﬁ-
Table 4 Correlation between SBP and BNP level in the
studied population.
SBP BNP r-Value p-Value
HE 211.3 324.33 0.22 0.43
HU 203 43 0.18 0.5
Control 140.5 8.13 0.11 0.74
Table 5 Correlation between DBP and BNP level in the
studied population.
DBP BNP r-Value p-Value
HE 129.67 324.33 0.33 0.21
HU 126 43 0.11 0.69
Control 84.5 8.13 0.22 0.52
Table 6 Correlation between MBP and BNP level in the
studied population.
MAP BNP r-Value p-Value
HE 156.6 324.33 0.24 0.38
HU 151.6 43 0.22 0.41
Control 103.13 8.13 0.25 0.48
Table 7 Correlation between PP and BNP level in the studied
population.
PP BNP r-Value p-Value
HE 81 324.33 0.11 0.69
HU 77 43 0.18 0.5
Control 56 8.13 0.08 0.81
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should include consideration of age.
Out of the thirty patients included, 17 were males (56.67%)
and 13 were females (43.33%). On comparison of BNP level
with both sexes we found no signiﬁcant difference in BNP level
between males (223.35 ± 179.2) and females (131.77 ± 255.2)
(p= 0.257).
This goes with the ﬁnding of Maisel et al. [20], who found
no signiﬁcant difference in BNP level between males and fe-Figure 2 Diagnostimales. But it doesn’t go with Ian Loke et al. [16], Redﬁeld
et al. [17], and Wang et al. [18], who did their studies on
healthy volunteers and found that BNP level was higher in fe-
males than in males, but they couldn’t clearly explain the phys-
iologic basis for these sex related differences. Only the
stimulatory effect of female sex hormones on natriuretic pep-
tide gene expression and extra cardiac sources of natriuretic
peptides within the female reproductive tract have been pro-
posed [21].
In our study; patients were grouped on the basis of clinical
ﬁndings into HE (15 pts) and HU (15 pts). HE patients were
subdivided into 6 patients with acute coronary syndrome
who accounted for 40% of HE cases; all of them presented
with unstable angina and 9 pts with neurological involvement
who accounted for 60% of HE cases and included 4 patients
with ischemic stroke (26.7%), 4 patients with hemorrhagic
stroke (26.7%), and only 1 patient with hypertensive encepha-
lopathy (6.6%).
In our study BNP level was signiﬁcantly higher in HE pa-
tients (324.33 ± 233.16) than HU patients (43 ± 13.5)
(p< 0.01) and it was higher in both groups than in the control
group (8.13 ± 5.8) (p< 0.01). But There was no signiﬁcant
difference in BNP level between HE patients with cardiac
and neurological involvement (p= 0.8) nor between patients
presenting with ischemic stroke, hemorrhagic stroke and
hypertensive encephalopathy (p= 0.3).
As in our study; Di somma et al. [19] found that BNP blood
level, in patients with highly elevated BP without organ dam-
age, was signiﬁcantly lower when compared with patients with
HE. Moreover, the same study found that the value of BNP in
the group of HU was roughly in the normal range as in young
healthy adults (20–25 pg/ml) in other studies [18], and hence
concluded that elevation of BP in HU does not cause an in-
crease of BNP level [19]. This is in contradistinction with our
ﬁndings that showed that BNP level was higher in both studied
groups than in the control group.
In addition, the above study found that BNP in HE was
greater in acute coronary syndrome subgroup when compared
with neurological subgroup [19]; and this does not go with our
study which found no signiﬁcant difference in BNP level be-
tween both groups. This could be explained by the fact that
our cases did not include myocardial infarction as in Di
Somma et al. study.
In contrast to Di Somma and our study; Ma¨kikallio et al.
[22] studied natriuretic peptides and mortality after stroke
and made a comparison in BNP values between acute phasesc value of BNP.
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stroke patients have equally high or even higher BNP plasma
values than the acute myocardial infarction patients.
BNP levels in patients with acute coronary syndrome was
studied by many authors as Kikuta et al. [23], who found that
the plasma levels of BNP are increased in patients with unsta-
ble angina when compared with healthy control subjects and
those with stable angina. Also, Sabatine et al. [24] discovered
that transient myocardial ischemia was associated with a rapid
increase in BNP concentration which is secreted by undam-
aged cardiomyocytes in patients with acute coronary syn-
drome, and this increase was proportional to the severity of
the ischemia.
Bassan et al. [25] analyzed the data of 631 patients diag-
nosed in the emergency room as myocardial infarction pre-
sented with chest pain and no ST-segment elevation on the
ECG and they showed signiﬁcantly higher BNP concentrations
on admission compared to those with unstable angina. Patients
with positive troponin values on admission demonstrated high-
er initial BNP concentrations compared to patients with nega-
tive initial results.
In aggregate the above ﬁndings suggest that transient ische-
mia increases wall stress and induce BNP synthesis and release
in proportion to the degree of ischemic insults. The level of
BNP may reﬂect the size or severity of ischemic insult even
when myocardial necrosis has not occurred [26,27].
Di Somma et al. found that BNP level in neurological sub-
group of HE was signiﬁcantly greater than in HU group and it
was supposed to be attributed to brain oedema [19]. Moreover,
other studies as Eguchi et al. [28], who studied the variation of
BP and neurohumoral factors during the acute phase of stroke,
found that BNP levels increased in the acute phase of stroke
and that there was a positive correlation between BP levels
and BNP levels. Also in the study of Tung et al. [29], on pa-
tients with subarachnoid hemorrhage, it was estimated that
plasma BNP levels in patients with hypertension were higher
than that in patients without hypertension.
Cakir et al. [30] found that plasma BNP levels in stroke pa-
tients with hypertension were higher than in stroke patients
without hypertension and there was no relationship between
plasma BNP levels and hemorrhage or infarction.
All the above studies done on BNP level in patients with
neurological insults go hand in hand with our results of higher
elevation of BNP level in hypertensive emergency cases with
neurological involvement.
In our study; both studied groups with their subdivisions as
well as in the control group there was no signiﬁcant correlation
between BNP level and systolic BP, diastolic BP, MAP and
Pulse Pressure. Di Somma et al. [19] found no signiﬁcant cor-
relation between BNP level and SBP, DBP and MAP in HE
and HU cases. While a statistical correlation was found be-
tween BNP level and PP in HU but not in HE studied patients.
Yan Hua et al. [31] found that plasma BNP levels increase with
increased PP, particularly PP > 7.98 kPa persons and this
contradict ﬁndings in our study.
In Cakir et al. [30], study on BNP level in acute ischemic
stroke and hypertension, they found positive correlation be-
tween plasma BNP levels and MAP.
In the study by Nakagawa et al. [32], it was found that
although patients with intracranial hemorrhage had higher
MAP levels than patients with ischemic stroke, the serum
BNP levels were higher in patients with ischemic stroke thanin those with intracranial hemorrhage. In the same study, it
was shown that there was a weak positive correlation between
the MAP levels and the BNP levels at the beginning of the
ischemic stroke.
Jabeen et al. [33] and Kato et al. [34] found positive corre-
lation between BNP level and SBP in patients with chronic
hypertension. BNP value in Jabeen et al. study was 27.06 ±
6 pg/ml in SBPP 140 mmHg [33]. Also Jabeen et al. [33]
and Jakubik et al. [35] found positive correlation between
BNP level and DBP in patients with chronic hypertension.
BNP value in Jabeen et al. study was 33.55 ± 8 pg/ml in dia-
stolic BPP 90 mmHg [33].
In our study, BNP at the cutoff point of 90 pg/ml demon-
strated a very high sensitivity and speciﬁcity in the diagnosis
and differentiation between HE and HU. The predictive value
of BNP concentration of >90 pg/ml for the diagnosis of HE
was 98%.
No studies could determine a clear limiting value of BNP as
regard HE as our study did, but studies done on heart failure
and acute coronary syndrome showed that patients with BNP
level of more than 80 pg/ml were signiﬁcantly more likely to
die, had a new or recurrent myocardial infarction, or had
new or progressive heart failure than those with a level of
80 pg/ml or less as studies done by Dao et al. and James
et al. [36,37]
Conclusion
BNP, a simple, rapid, and easy test to perform and interpret, can
be used as an early marker for the heart and brain involvement
during hypertensive crises. Its evaluation could be very useful in
patients admitted with acute and rapid elevation of BP.
Limitations
We are aware of some limitations of our study. One of them is
that a BNP determination at discharge time should be very
useful to eventually clarify if increased level of BNP in HE is
related or not to acute heart or brain injury or to the transient
pathophysiological modiﬁcation.
Recommendations
We recommend continuing the study on a wide scale of pa-
tients to declare the use of BNP as a routine investigation in
the ER or ICU to distinguish HE from HU and immediately
identify patients who need further evaluation to limit target or-
gan damage.
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